[HTML][HTML] Precision medicine in breast cancer

Y Naito, T Urasaki - Chinese Clinical Oncology, 2018 - cco.amegroups.org
Precision medicine is a strategy for disease treatment and prevention that considers
individual variability in genes, environment, and lifestyle. Historically, breast cancer has been …

[HTML][HTML] Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma

…, Y Sato, R Asaka, N Fukuda, X Wang, T Urasaki… - Modern Pathology, 2021 - Elsevier
Neuroendocrine carcinoma (NEC) of the head and neck is a rare type of malignancy,
accounting for only 0.3% of all head and neck cancers, and its clinicopathological and genomic …

[HTML][HTML] Recent advances in medical therapy for urological cancers

T Yuasa, T Urasaki, R Oki - Frontiers in Oncology, 2022 - frontiersin.org
Currently, the paradigm of medical treatment for patients with metastatic urological cancer is
dramatically changing. Tyrosine kinase inhibitors, androgen deprivation therapy, and …

Sequential analysis of neutrophil-to-lymphocyte ratio for differentiated thyroid cancer patients treated with lenvatinib

N Fukuda, X Wang, A Ohmoto, T Urasaki, Y Sato… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated
with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR…

Efficacy of paclitaxel-based chemotherapy after progression on nivolumab for head and neck cancer

Y Sato, N Fukuda, YU Fujiwara, X Wang, T Urasaki… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC),
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …

First‐in‐human study of E7130 (a tumor microenvironment‐ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose …

…, Y Naito, Y Kuboki, K Harano, M Ono, T Urasaki… - Cancer, 2023 - Wiley Online Library
Background E7130 is a novel anticancer agent created from a total synthetic study of
norhalichondrin B. The authors report the E7130 dose‐escalation part of a first‐in‐human study of …

Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib

…, K Toda, YU Fujiwara, X Wang, A Ohmoto, T Urasaki… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer
(ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this …

[HTML][HTML] Pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of pazopanib treatment for soft-tissue sarcoma

Y Sato, K Nakano, X Wang, N Fukuda, T Urasaki… - Cancers, 2021 - mdpi.com
Simple Summary Second-line systematic therapy options for soft-tissue sarcoma (STS)
have remained unchanged for decades due to the rarity and various histological types …

Mycophenolate mofetil as a successful treatment of corticosteroid-resistant immune checkpoint inhibitor-induced hepatitis

…, M Nishizawa, N Fukuda, T Urasaki… - Oxford Medical Case …, 2020 - academic.oup.com
Immune checkpoint inhibitors (ICIs) are now widely used to many malignant diseases, but
some patients suffer from immune-related adverse events during or after ICI treatments. The …

[HTML][HTML] Case report: a case of trimethoprim/sulfamethoxazole-triggered hypotensive shock: cytokine release syndrome related to immune checkpoint inhibitors and …

T Urasaki, M Ono, T Mochizuki, K Takeda… - Frontiers in …, 2021 - frontiersin.org
Currently, only a few reports exist on the cytokine release syndrome (CRS) as one of the
severe immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs). …